本帖最后由 老马 于 2013-3-13 13:43 编辑 , s" q$ m+ f l' |- b8 |. Q
4 n5 y- o k# w% [( ~
健择(吉西他滨)+顺铂+阿瓦斯汀& I4 P& P/ T( h- x
Gemzar +Cisplatin + Avastin
6 Z" J, t5 @2 s u- t( r3 whttp://annonc.oxfordjournals.org/content/21/9/1804.full4 q. e( ^% m9 k( s
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 6 r9 H2 f0 T& q! A$ Z
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
5 }0 ]+ ?/ G3 H4 lResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
2 W a; g: p$ v- b
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 835)
/ ^0 n* _. t. v. c4 v华为网盘附件:1 J9 \% b9 O2 j& l: J: R/ D1 r- M
【华为网盘】ava.JPG' k7 _5 H3 T5 ?* d9 a
|